|
|
|
|
|
|
|
|
|
|
|
27.11.25 - 10:27
|
QIAGEN Aktie: Fundamentale Schwächen bremsen den langfristigen Ausblick (Aktiencheck)
|
|
|
Frankfurt (www.aktiencheck.de) - QIAGEN-Aktienanalyse von XTB:
Die Experten von XTB nehmen die Aktie der QIAGEN N.V. (ISIN: NL0015002CX3, WKN: A40ZZU, Ticker-Symbol: QIA, NYSE-Symbol: QGEN) in einer aktuellen Marktanalyse unter die Lupe.
Im Rahmen ihres "Aktien Marathon" würden die Experten von XTB wöchentlich eine ausgewählte Aktie anhand fundamentaler Kennzahlen und langfristiger Projektionen bewerten. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.11.25 - 14:03
|
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December (GlobeNewswire EN)
|
|
|
NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:...
|
|
|
|
|
|
|
|